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A B S T R A C T 
Introduction: Patients who undergo partial 
nephrectomy have been shown to be at decreased 
risk of renal impairment compared with radical 
nephrectomy. We examined the oncological outcome 
of patients in our centre who underwent partial or 
radical nephrectomy for T1 renal cancer (7 cm or 
smaller), and compared the likelihood of developing 
chronic kidney disease.
Methods: This historical cohort study with internal 
comparison was conducted in a tertiary hospital in 
Hong Kong. A cohort of 86 patients with solitary 
T1 renal cancer and a normal contralateral kidney 
who underwent radical (38 patients) or partial (48 
patients) nephrectomy between January 2005 and 
December 2010 was included. The overall and 
cancer-free survival, change in glomerular filtration 
rate, and new onset of chronic kidney disease 
were compared between the radical and partial 
nephrectomy groups.
Results: A total of 32 (84%) radical nephrectomy 
patients and 43 (90%) partial nephrectomy patients 
were alive by 31 December 2012. The mean follow-
up was 43.5 (standard deviation, 22.4) months. 
There was no significant difference in overall 
survival (P=0.29) or cancer-free survival (P=0.29) 
Partial nephrectomy for T1 renal cancer can 
achieve an equivalent oncological outcome 
to radical nephrectomy with better renal 
preservation: the way to go
Introduction
With the widespread use of advanced imaging such 
as computed tomography (CT), many renal tumours 
are now incidentally discovered before the patient 
becomes symptomatic. These tumours are often 
of small size. This has led to the emerging practice 
of partial nephrectomy (PN) rather than radical 
nephrectomy (RN) that has been the gold-standard 
treatment for localised renal tumours for over 40 
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renal preservation than radical nephrectomy.  
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recommend partial nephrectomy for T1a and selected T1b renal cancers, provided that relevant expertise is 
available.
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years.1 Studies have shown that cancer control can 
be achieved by PN in patients with T1a tumours,2-5 
and some studies also supported the extended use 
of PN for T1b tumours.6-9 In addition, patients who 
undergo PN have been shown to be at decreased risk 
of renal impairment.10
 Nonetheless, many surgeons in Hong Kong 
continue to perform RN for all renal tumours, 
regardless of their size. The major concerns are the 
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between the two groups. Both groups enjoyed 
good oncological outcome with no recurrence in 
the partial nephrectomy group. Overall, 18 (21%) 
patients had pre-existing chronic kidney disease. The 
partial nephrectomy group had a significantly smaller 
median reduction in glomerular filtration rate (12.6% 
vs 35.4%; P<0.001), and radical nephrectomy carried 
a significantly higher risk of developing chronic 
kidney disease (hazard ratio=5.44; 95% confidence 
interval, 1.26-23.55; P=0.02).
Conclusions: Compared with radical nephrectomy, 
partial nephrectomy can prevent chronic kidney 
disease and still achieve an excellent oncological 
outcome for T1 renal tumours, in particular T1a 
tumours and tumours with a low R.E.N.A.L. score. 
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T1期腎癌患者進行腎部分切除術的療效可媲美
根治性全腎切除術並能較好地保留腎功能： 
治療腎癌患者的一個可取方法
賴俊廷、馬偉傑、姚銘廣
引言：研究顯示腎部分切除術所帶來的腎功能損害風險比腎癌根治術
低。本研究探討T1期腎癌患者（腫瘤大小為7 cm或以下）進行腎部分
切除術或根治性全腎切除術的療效，並比較兩種手術發展成慢性腎病
的可能性。
方法：這是在香港一所提供第三層醫療服務的醫院進行內部比較的歷
史隊列研究。於2005年1月至2010年12月期間到上述中心應診的86
名單發T1期腎癌的患者均被列入研究範圍。所有患者的對側腎均為正
常；當中有38例進行根治性全腎切除術，另48例進行腎部分切除術。
研究把兩組的總體生存率和無瘤生存率、腎小球濾過率的變化和慢性
腎病的新發病例進行比較。 
結果：直至2012年12月31日為止，32例（84%）根治性全腎切除術
和43例（90%）腎部分切除術的患者仍然生存。平均隨訪時間為43.5
（標準差22.4）個月。兩組間的總體生存率（P = 0.29）和無瘤生存率
（P = 0.29）無顯著差異。所有患者均有良好的術後結果；腎部分切除
術的患者亦沒有復發。18例（21%）原有慢性腎病。腎部分切除術患
者的腎小球濾過率的下降率明顯較低（12.6%比35.4%，P<0.001）。
根治性全腎切除術患者患上慢性腎病的風險顯著較高（風險比=
5.44；95%置信區間：1.26-23.55；P=0.02）。
結論：與根治性全腎切除術比較，腎部分切除術可預防慢性腎病，而
且對於T1期腎癌患者來說能達至極佳的療效，對於T1a期腫瘤以及具
有低R.E.N.A.L.分數的患者尤其有效。
technical difficulty of PN and the associated major 
postoperative complications.
 The aim of this study was to compare the 
oncological outcome, survival, and changes in 
renal function in patients who underwent RN or 
PN for T1 renal cancer in our centre. Patients were 
predominantly of Chinese ethnicity.
Methods
We retrospectively reviewed the data of patients who 
underwent RN or PN at our centre between January 
2005 and December 2010. Patients with a solitary 
tumour of 7 cm or less in diameter and a normal 
contralateral kidney were included. The decision to 
perform PN was based on tumour characteristics 
(size, proximity to collecting system and major 
vessels) and the surgeon’s preference. Exclusion 
criteria were: end-stage renal failure (glomerular 
filtration rate [GFR] <15 mL/min/1.73 m2), history 
of renal transplantation, known hereditary renal 
cancer, known poor or non-functioning contralateral 
kidney, history of nephrectomy, and preoperative 
evidence of tumour metastases.
 Preoperative parameters including age, gender, 
serum creatinine, and estimated GFR were studied. 
We used the modified Charlson-Romano index to 
compare patient co-morbidity.11 We also compared 
postoperative outcome for the RN and PN groups, 
including length of hospital stay, complications, 
and 90-day mortality. Severity of complications 
was graded using the Clavien-Dindo classification 
system.12
 Our study outcome included 5-year overall 
survival, cancer-free survival, change in renal 
function in terms of estimated GFR (eGFR), and 
new onset of chronic kidney disease (CKD)—GFR 
was calculated with the four-variable Modification 
of Diet in Renal Disease formula: eGFR = 32 788 x 
serum creatinine (μmol/L)-1.154 x age-0.203 x [1.212 
if black] x [0.742 if female]13; CKD was defined 
as GFR of <60 mL/min/1.73 m2. Patients were 
followed up according to international guidelines, 
with slight variation in timing of imaging due to 
examination waiting time issues. In general, follow-
up was scheduled every 3 months within the first 
year of operation with measurement of serum 
creatinine and GFR, and CT scan was performed 
approximately 12 months following surgery. Patients 
were subsequently followed up every 6 months, with 
renal function checked at each visit, and imaging 
studies (ultrasonography or CT) performed annually 
for the first 5 years and thereafter once every 2 years. 
 For preoperative characteristics and 
postoperative outcome, P value was determined by 
the Chi squared test and Mann-Whitney U test for 
categorical and continuous variables, respectively. 
Kaplan-Meier model was used for 5-year overall 
and cancer-free survival, and the postulated 5-year 
probability of freedom from CKD. Risk of new onset 
of CKD was calculated with Cox proportional hazards 
regression, adjusted for age, Charlson Comorbidity 
Index (CCI), preoperative GFR, gender, and tumour 
size; with time to CKD development as dependent 
variable; death, loss to follow-up, or last follow-
up date before 31 December 2012 were censored 
in the analysis. Overall survival was analysed by 
Cox proportional hazards regression adjusted with 
Fuhrman grade of tumour, in addition to the above 
factors. We did not include diabetes mellitus as it 
was included in the CCI. We considered a 2-sided P 
value of <0.05 as statistically significant. All statistical 
analyses were performed with the Statistical Package 
for the Social Sciences (Windows version 20.0; SPSS 
Inc, Chicago [IL], US).
Results
A total of 86 patients were reviewed, with a mean 
(± standard deviation) follow-up time of 43.5 ± 22.4 
months. Four (5%) patients were lost to follow-up 
with their status unknown by the end of our study. 
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Overall, RN was performed in 38 patients and PN in 
48. Age, gender, and preoperative serum creatinine 
level and GFR were similar between the two groups. 
The mean age of RN and PN groups was 61 years 
and 63 years, respectively (P=0.48), with a respective 
mean preoperative GFR of 80.8 mL/min/1.73 m2 and 
75.0 mL/min/1.73 m2 (P=0.38). Six (16%) patients 
in the RN group and 11 (23%) in the PN group had 
a preoperative GFR of <60 mL/min/1.73 m2; one 
patient in the PN group had a preoperative GFR of 
<30 mL/min/1.73m2. Most patients in the RN and 
PN groups had a CCI of <2 (84% vs 85%; P=0.87). 
The respective mean follow-up time was 42.1 ± 24.0 
and 44.5 ± 21.3 months (P=0.62) [Table 1].
 Tumours were more complex in the RN group 
in terms of the R.E.N.A.L. score14 derived from 
preoperative CT (8.4 vs 6.7, P<0.001). The mean 
tumour size, based on final pathological examination, 
was also larger in the RN group (4.8 cm vs 2.5 cm, 
P<0.001). In the RN group, 24 (63%) patients had 
a T1b tumour compared with three (6%) in the PN 
group (P<0.001). Comparison of the first half of 
our study period (2005-2008) with the second half 
(2009-2010) revealed that tumour characteristics 
were similar in the PN group, in terms of both size 
(2.4 cm vs 2.5 cm; P=0.93) and R.E.N.A.L. score 
(6.2 vs 7.0; P=0.32). Most tumours in both groups 
were of the clear cell type. The RN group had more 
Fuhrman grade 3 tumours but the difference was 
not significant (Table 1). All resections enjoyed clear 
resection margins on final pathological examination.
 All RNs were performed via a laparoscopic 
approach. An open procedure was performed for 29 
(60%) of the PNs, eight (17%) were performed via a 
laparoscopic approach, and 11 (23%) with robotic 
assistance. Of the latter, conversion to an open 
procedure was required in two cases. Operating 
time was significantly longer in the PN group (250 
mins vs 345 mins; P<0.001). None of the PNs were 
converted to RN.
 All PNs were performed with vascular control 
achieved by hilar clamping. Overall, 28 (58%) PNs 
were performed with cold ischaemia using ice slush, 
with a mean cold ischaemia time of 70 minutes; 
among these, 23 (82%) were an open procedure 
and two were conversion of robotic-assisted 
laparoscopic PN to open procedure. Of the PNs, 20 
(42%) were performed with warm ischaemia, and 
the mean warm ischaemia time was 32 minutes; 
all laparoscopic PNs were performed with warm 
ischaemia. The complexity of tumour in terms of 
R.E.N.A.L. score was significantly lower in the warm 
ischaemia group (5.7 vs 7.5; P=0.01).
 Patients in the PN group had a longer 
postoperative hospital stay (6 vs 13 days; P<0.001); 
one of whom died within 90 days of surgery of 
cholecystitis and septic complications unrelated to 
the renal cancer.
 Postoperative complication rates were similar 
between the two groups (P=0.19), although the 
PN group had more Clavien grade III or above 
complications (0% vs 10%; Table 2). Four patients 
had persistent urine leakage that was successfully 
treated with retrograde injection of surgical adhesive 
glue; one patient developed pseudoaneurysm of the 
segmental branch of the renal artery, which was 
treated by angiographic embolisation. No long-term 
morbidity or mortality occurred. Complication rate 
was not associated with patient age, CCI, R.E.N.A.L. 
TABLE 1.  Patient demographics and tumour characteristics
Demographic/characteristic No. (%) of patients or mean ± SD P value
RN (n=38) PN (n=48)
Gender 0.82
Male 27 (71) 32 (67)
Female 11 (29) 16 (33)
Age at diagnosis (years) 61 ± 14 63 ± 14 0.48
Preop serum creatinine (μmol/L) 87.7 ± 21.6 95.3 ± 32.4 0.52
Preop GFR (mL/min/1.73 m2) 80.8 ± 22.6 75.0 ± 23.5 0.38
Preop CKD stage 0.83
1 12 (32) 12 (25)
2 20 (53) 24 (50)
3 6 (16) 11 (23)
4 0 1 (2)
Charlson Comorbidity Index 0.87
<2 32 (84) 41 (85)
≥2 6 (16) 7 (15)
Length of follow-up (months) 42.1 ± 24.0 44.5 ± 21.3 0.62
R.E.N.A.L. score* 8.4 ± 1.7 6.7 ± 1.8 <0.001
Tumour size (cm) 4.8 ± 1.2 2.5 ± 1.1 <0.001
Tumour stage <0.001
T1a 14 (37) 45 (94)
T1b 24 (63) 3 (6)
Pathology 0.31
Clear cell 36 (95) 41 (85)
Papillary 0 4 (8)
Chromophobe 2 (5) 2 (4)
Multilocular cystic RCC 0 1 (2)
Fuhrman grade 0.08
1 3 (8) 10 (21)
2 21 (55) 29 (60)
3 14 (37) 9 (19)
Abbreviations: CKD = chronic kidney disease; GFR = glomerular filtration rate; PN = 
partial nephrectomy; Preop = preoperative; RCC = renal cell carcinoma; RN = radical 
nephrectomy; SD = standard deviation
* R.E.N.A.L. score = Radius (maximal diameter in cm), Exophytic/endophytic 
properties, Nearness of tumour to the collecting system or sinus (mm), Anterior/
posterior, Location relative to polar lines; R.E.N.A.L. score was missing in 33 patients
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score of tumour, or operative parameters (operative 
approach, operating time, and ischaemia time).
 An overall excellent oncological outcome was 
achieved by both groups. Extensive metastases were 
evident 3 months after operation in one patient in 
the RN group but these were not apparent before 
operation. By 31 December 2012, 32 (84%) RN and 
43 (90%) PN patients were alive. The overall 5-year 
survival for the RN and PN groups was 84.2% and 
89.6% (P=0.29) respectively, and the cancer-free 
survival was 97% and 100% (P=0.29) respectively. 
Both RN and PN did not affect overall survival 
(hazard ratio=0.84; 95% confidence interval [CI], 
0.17-4.02; P=0.82), after adjustment for age, CCI, 
preoperative GFR, gender, tumour size, and Fuhrman 
grade (Table 3).
 Patients who underwent RN had a greater 
median reduction in GFR than PN patients (35.4% 
vs 12.6%; P<0.001), and the degree of reduction was 
most distinctive in the first year after operation (Fig 
1). In the PN group, one patient with a preoperative 
GFR of 30 mL/min/1.73 m2 developed stage 5 CKD 
4 years after surgery and required renal replacement 
therapy. Preoperative GFR was >60 mL/min/1.73 m2 
in 32 patients in the RN group and in 36 patients 
in the PN group. At their last follow-up, CKD was 
developed in 18 (56%) patients who underwent RN 
but new-onset CKD was evident in only five (14%) 
of the PN group (P<0.001). The majority of the CKD 
cases were stage 3 (94% in RN group and 80% in 
PN group); none was in stage 5. Cox proportional 
hazards regression model showed that RN was 
the most significant factor contributing to the 
development of CKD (RN vs PN, hazard ratio=5.44; 
95% CI, 1.26-23.55; P=0.02; Table 4). The postulated 
probability of freedom from new-onset CKD in 5 
years, by Kaplan-Meier model, was 33% and 81% in 
the RN and PN groups, respectively (P<0.001; Fig 2).
Discussion
Many surgeons have underestimated the impact of 
renal impairment after RN for renal cancer, on the 
basis that organ donors who undergo nephrectomy 
are not at increased risk of renal failure or death.15-17 
Nonetheless, donors represent a different population 
as they are often young and fit. Patients with renal 
cancer are often older and have co-morbidities 
such as hypertension and diabetes mellitus. In 
our study, 21% of our patients had a GFR of <60 
mL/min/1.73 m2 prior to surgery and 15% had a 
CCI of ≥2. Therefore it is logical that this cohort of 
patients may benefit from a surgical technique that 
preserves more of their renal function.
 Our study showed that PN resulted in less 
renal deterioration in terms of GFR, with RN having 
a hazard ratio of 5.44 for development of CKD, after 
taking into consideration the patient co-morbidities, 
gender, age, and tumour size. The postulated 
TABLE 2.  Postoperative outcomes
Outcome No. (%) of patients or mean ± SD P value
RN (n=38) PN (n=48)
Length of hospital stay (days) 6 ± 6 13 ± 12 <0.001
Complications 0.19
Urine leakage 0 4 (8)
Ileus 1 (3) 1 (2)
Urinary tract infection 1 (3) 1 (2)
Urinary retention 1 (3) 2 (4)
Renal artery pseudoaneurysm 0 1 (2)
Acute tubular necrosis 0 1 (2)
Lymph leakage 0 1 (2)
Clavien classification 0.06
I 3 (8) 3 (6)
II 0 1 (2)
IIIa 0 5 (10)
IIIb 0 0
IV 0 0
V 0 0
90-Day mortality 0 1 (2) <0.001
Abbreviations: PN = partial nephrectomy; RN = radical nephrectomy; SD = standard 
deviation
TABLE 3.  Factors associated with overall survival
TABLE 4.  Factors associated with new-onset chronic kidney disease after operation
Factor Hazard ratio (95% CI) P value
Type of nephrectomy (RN vs PN) 0.84 (0.17-4.02) 0.82
Age 1.11 (1.02-1.22) 0.02
Charlson Comorbidity Index 1.55 (0.82-2.93) 0.18
Preoperative GFR 1.03 (0.98-1.07) 0.21
Gender (female vs male) 1.74 (0.33-9.05) 0.51
Tumour size 1.54 (0.90-2.62) 0.11
Fuhrman grade 0.96 (0.29-3.24) 0.95
Factor Hazard ratio (95% CI) P value
Type of nephrectomy (RN vs PN) 5.44 (1.26-23.55) 0.02
Age 1.02 (0.90-1.06) 0.52
Charlson Comorbidity Index 1.45 (0.80-2.61) 0.22
Preoperative GFR 0.96 (0.91-1.01) 0.09
Gender (female vs male) 0.78 (0.31-1.99) 0.60
Tumour size 0.87 (0.57-1.34) 0.53
Abbreviations: CI = confidence interval; GFR = glomerular filtration rate; PN = partial 
nephrectomy; RN = radical nephrectomy
Abbreviations: CI = confidence interval; GFR = glomerular filtration rate; PN = partial 
nephrectomy; RN = radical nephrectomy
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probability of freedom from new onset of CKD in 
5 years in our series was 33% following RN and 81% 
following PN. This echoes the finding of Huang et 
al10 who reported the 3-year probability of freedom 
from new onset of CKD as 35% after RN and 80% 
after PN; RN remained an independent risk factor 
for development of new-onset CKD with a hazard 
ratio of 3.82.
 A community-based study showed that CKD 
was an independent risk factor for the development 
of cardiovascular events, hospitalisation, and death.18 
In a population-based cohort of 7769 patients, RN 
was associated with a 1.23-fold increase in overall 
mortality compared with PN (P=0.001), and a higher 
rate of non–cancer-related mortality.19 Huang et al10 
also demonstrated that RN was associated with a 
1.46-fold increased risk of overall mortality, although 
the risk of a cardiovascular event was not increased 
in the RN group. Evidence that PN decreases overall 
mortality remains contradictory. A randomised 
controlled trial showed that RN had comparable 
overall survival with PN after a median follow-up of 
9.3 years.20 In our study we did not show a significant 
difference in overall survival between PN and RN 
groups.
 Another concern of PN is its cancer control, 
since the prevention of local recurrence is of 
paramount importance. The extent of resection is 
affected by tumour size, proximity to the collecting 
system, and location and degree of exophytic growth. 
It is generally accepted that PN can achieve excellent 
oncological outcome for tumours smaller than 4 
cm, with a long-term 5-year and 10-year cancer-
free survival rates of 92% to 100%.2,21-23 Studies have 
demonstrated the feasibility of PN for tumours larger 
than 4 cm without compromising the oncological 
outcome, although there was a higher risk of peri-
operative bleeding and other complications.23,24 
In our cohort, we achieved a 100% clear surgical 
resection margin with PN, and no local recurrence 
was found after 5 years. 
 Increased peri-operative morbidity is 
traditionally a concern in PN. There were more 
Clavien grade III complications and a longer hospital 
stay for patients who underwent PN in our cohort. 
The most common complication in an open PN 
series was urine leakage, with a mean incidence of 
6.5% (range, 2.1%-17%).25,26 In a multicentre review 
of 51 laparoscopic PNs, postoperative urine leakage 
was observed in three (6%) patients.27 The results 
of a previous series by Gill et al,28 supported by 
our results, suggested that both tumour location 
and diameter were not related to the occurrence of 
urine leakage. In contrast to the logical thinking that 
calyceal entry was not observed during renorrhaphy, 
it has been suggested that central coagulation 
necrosis with electrocautery is responsible for 
fistula formation.27 The use of a ureteral catheter and 
FIG 1.  Change of glomerular filtration rate (GFR) after surgery of patients 
undergoing partial nephrectomy (PN) and radical nephrectomy (RN)
RN patients had a higher median reduction in GFR than PN patients (35.4% vs 12.6%; 
P<0.001), and the difference was most distinctive in the first year after operation, and 
sustained throughout the years
FIG 2.  The postulated probability of freedom from new-onset chronic kidney 
disease (CKD) in 5 years was 33% and 81% in radical nephrectomy (RN) and 
partial nephrectomy (PN) groups, respectively (P<0.001)
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retrograde dye injection after haemostasis has been 
advocated to help identify any calyceal opening, 
but this was not supported in a retrospective series 
by Bove et al29 that involved 54 patients with and 
49 patients without ureteral catheter placement. 
We believe that the adoption of cold cutting and 
elevation of the tumour from the tumour bed by the 
suction cannula, which also simultaneously aspirates 
the blood, can avoid coagulation necrosis and a 
clear operative field can be maintained so that any 
breaching of calyceal integrity can be identified. The 
use of a ureteral catheter can be an adjunct measure 
in equivocal cases when the tumour is abutting the 
calyceal lining on preoperative imaging.
 Our study have some limitations. Since it was 
a retrospective study, patients were not randomised 
and there was a selection of smaller and less complex 
tumours in the PN group. There were also other 
confounding factors such as patient’s smoking status 
that were not included, hence the two groups were 
not totally comparable, although other patient 
demographics were similar. As a proportion of 
preoperative imaging could not be retrieved, the 
R.E.N.A.L. score could not be calculated for every 
patient included, and this contributed another 
confounding factor. Only three patients had T1b 
renal cancer in the PN group, thus the oncological 
outcome may be more certain in T1a renal cancer. 
Our stratified analysis in T1a renal cancer had 
a similar result with PN having an equivalent 
oncological outcome and superior renal function 
preservation, although the result is not shown here. 
In addition, the risk of tumour recurrence, negative 
effect of CKD and their effect on survival might not 
be truly reflected in our relatively short follow-up 
time. Nonetheless with experience, renal tumours of 
4 cm or more in diameter may be amenable to safe 
PN with equivalent oncological outcome and a lower 
chance of progression to CKD. This may translate 
into improved overall survival.30
Conclusions
Partial nephrectomy can preserve more renal 
function and reduce the risk of development of CKD 
compared with RN. Excellent cancer control and a 
low local recurrence rate can still be achieved with 
PN for T1 tumours, in particular T1a tumours and 
tumours with a low R.E.N.A.L. score. Although 
RN continues to constitute a significant proportion 
of surgical procedures for T1 renal cancer in our 
locality, we recommend that, if technically feasible, 
PN should be performed for all T1a and selected T1b 
renal cancers.
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